

## Talazoparib Dose Modification

### Disclaimers

- This document has been approved for use in Australia by Pfizer Oncology Medical colleagues in response to unsolicited requests on this topic, and may not be distributed
- This document includes information of an off-label nature. Pfizer does not suggest or recommend the use of any Pfizer products in any manner other than as described in the TGA approved Prescribing Information ([www.tga.gov.au](http://www.tga.gov.au))
- Talazoparib has not been approved by the TGA for use in prostate cancer and has not been found safe or effective

### Dose Modification Tables

Table 1. Recommended dose reduction levels for adverse reactions in mCRPC when used in combination with enzalutamide<sup>1</sup>

Dose Reductions	Dose Level
Recommended starting dose <sup>2</sup>	0.50 mg once daily
1 <sup>st</sup> dose reduction <sup>a</sup>	0.35 mg once daily
2 <sup>nd</sup> dose reduction	0.25 mg once daily
3 <sup>rd</sup> dose reduction	0.10 mg once daily

Table 2. Recommended dose levels in mCRPC when used after 6 weeks of enzalutamide discontinuation<sup>1,b</sup>

Talazoparib dose at enzalutamide discontinuation	Talazoparib levels 6 weeks from enzalutamide discontinuation
0.50 mg	1.00 mg once daily
0.35 mg	0.75 mg once daily
0.25 mg	0.50 mg once daily
0.10 mg	0.20 mg once daily

mCRPC: metastatic castration-resistant prostate cancer; For enzalutamide dose reductions, please refer to the TGA website<sup>3</sup>

<sup>a</sup>Starting dose for patients with moderate renal impairment (eGFR 30-59 mL/min/1.73m<sup>2</sup> based on [MDRD](#) equation)<sup>1</sup>

<sup>b</sup>After escalation, talazoparib dose can be reduced in 0.25 mg decrements to manage adverse events. Patients on 0.20 mg can dose reduce to 0.10 mg<sup>1</sup>

### References

1. Agarwal N et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. *The Lancet*. 2023. DOI: [https://doi.org/10.1016/S0140-6736\(23\)01055-3](https://doi.org/10.1016/S0140-6736(23)01055-3)
2. Agarwal N, et al. ASCO Annual Meeting 2019, Abstract 5076
3. [Therapeutic Goods Administration \(TGA\)](#) (Accessed 18/09/2023)